MOLOGEN AG
MOLOGEN AG: Presentation on IMPACT study at ESMO Symposium on Immuno-Oncology
MOLOGEN AG / Key word(s): Study results MOLOGEN AG: Presentation on IMPACT study at ESMO Symposium on Immuno-Oncology Berlin, November 17, 2014 – MOLOGEN, a biotechnology company, announced today that data on long-term treated metastatic colorectal cancer patients from the IMPACT study will be presented at the ESMO Symposium on Immuno-Oncology 2014. The Symposium will take place on November 21-22 in Geneva. IMPACT was a randomized placebo-controlled phase II trial with the cancer immune therapy MGN1703 in metastatic colorectal cancer. Prof. Dr. Werner Scheithauer, Clinical Division of Oncology, Department of Medicine I, University Hospital in Vienna, Austria, one of the coordinating investigators of the IMPACT trial, will present the data in his lecture at the “Best Abstracts Session”. Abstract details: Best Abstracts Session: November 21, 2014 at 5.25 pm – 6.45 pm. The abstract will be published in the ESMO Symposium on Immuno-Oncology 2014 Abstract Book, a supplement to the official ESMO journal Annals of Oncology. For more information on the ESMO please visit ESMO’s website: About IMPACT Patients included in the IMPACT study had stabilization, or partial or complete remission of their disease after receiving first-line therapy for 4.5 to 6 months. The Patients were randomized to receive either MGN1703 or placebo twice per week. The treatment was continued until tumor progression was observed. The primary endpoint of the study was to determine progression-free survival of the patients. Secondary study endpoints included overall survival, progression-free survival from start of induction therapy, response rates and safety, as well as collection of immunological and pharmacodynamic data. About MGN1703 MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
17.11.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | info@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
297438 17.11.2014 |